Dow Jones
34.364,50 +99,13 (+0,29%) Nasdaq
13.855,13 +86,21 (+0,63%) Nikkei 225
27.113,13 -475,24 (-1,72%) EUR/USD
1,1325 -0,0005 (-0,05%) BTC-EUR
31.876,40 -131,17 (-0,41%) CMC Crypto 200
821,53 +10,93 (+1,35%)
Emergent BioSolutions Inc. (0IGA.L)
| Chiusura precedente | 50,63 |
| Aperto | 44,82 |
| Denaro | 0,00 x N/D |
| Lettera | 0,00 x N/D |
| Min-Max giorno | 44,56 - 44,82 |
| Intervallo di 52 settimane | 44,56 - 44,82 |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | 1,968B |
| Beta (5 anni mensile) | 0,93 |
| Rapporto PE (ttm) | 10,65 |
| EPS (ttm) | 4,18 |
| Prossima data utili | 09 gen 2022 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
Founder and Executive Chairman of Emergent BioSolutions Announces Retirement
Fuad El-Hibri to Retire After More Than 20 YearsGAITHERSBURG, Md., Jan. 14, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that Fuad El-Hibri, founder and executive chairman, has decided to retire effective April 1, 2022. “Creating and leading Emergent has been the honor of my life, and it would not have been possible without the help of our incredible team,” said El-Hibri. “I want to thank everyone at Emergent, past and present, for helping advance our inspiring
- GlobeNewswire
Emergent BioSolutions Announces 2022 Financial Guidance, Provides Preliminary 2021 Results
Expects a re-baseline of operations with stable revenue contributions from core products and services business in 2022, guiding to total revenues of $1.45 billion at the midpoint and Adjusted EBITDA margin of 21.5% at the midpointReports preliminary 2021 total revenues of $1.78 billion at the midpoint and Adjusted EBITDA of $513 million, or 29%, at the midpoint, both in line with prior guidance given in November 2021 GAITHERSBURG, Md., Jan. 09, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc.
- GlobeNewswire
Emergent BioSolutions to Participate in Investor Conferences
GAITHERSBURG, Md., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following investor conferences in the first quarter of 2022: 40th Annual J.P. Morgan Healthcare Conference January 10 to 13, 2022Company presentation scheduled on January 10 at 8:15 am PSTClick for Webcast J.P. Morgan 2022 Global High Yield & Leveraged Finance ConferenceFebruary 28 to March 2, 2022Company prese
